Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Puerarin is a bioactive isoflavone derived from kudzu root that acts as a selective estrogen receptor modulator (SERM) and cardiovascular protective compound. It primarily works by modulating estrogen receptors, improving cardiac function, and enhancing endothelial nitric oxide production.
Origin & History
Puerarin is a major bioactive isoflavone (8-C-glucoside of daidzein) extracted primarily from the dried root of Pueraria lobata (Kudzu vine), a perennial leguminous plant native to East Asia. It is obtained through ethanol extraction, purification, and sometimes chromatography, constituting 20-60 mg/g in crude P. lobata root extracts.
Research Narrative (Provisional)
Multiple meta-analyses support puerarin injection's cardiovascular benefits, including a 2025 analysis of 29 RCTs (n=2,480; PMID: 40391374) for chronic heart failure and a 2022 analysis of 8 RCTs (n=388; PMC9357890) for acute heart failure, both showing significant improvements versus conventional therapy. A meta-analysis of 32 RCTs (PMID: 28072733) demonstrated efficacy for acute ischemic stroke, with ongoing trials investigating metabolic conditions (ChiCTR2400094017, NCT06494683).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Puerarin is a pure isoflavone compound (C21H20O9), not a whole food ingredient, therefore it has no macronutrient, vitamin, mineral, or fiber content. Key bioactive profile: Primary compound is puerarin (daidzein-8-C-glucoside) at ≥98% purity in standardized extracts. Molecular weight: 416.38 g/mol. Typical therapeutic doses range from 200–500 mg/day (oral) or 250–500 mg/day (intravenous injection in clinical settings). Bioavailability notes: Oral bioavailability is relatively low (~3–13%) due to limited intestinal absorption of C-glycoside structure, as it resists hydrolysis by intestinal glucosidases unlike O-glycosides; intravenous administration bypasses this limitation and is commonly used in Chinese clinical trials. Peak plasma concentration (Tmax) reached approximately 1–2 hours post oral ingestion. Half-life (t1/2) approximately 3–5 hours. The compound is primarily extracted from Pueraria lobata (kudzu root), where puerarin constitutes approximately 1–2% of dry root weight. Secondary isoflavones co-occurring in source plant include daidzein (~0.1–0.5%), daidzin, and formononetin, but these are absent in isolated puerarin compound form. Puerarin acts as a phytoestrogen with weak estrogenic activity (estimated 1/1000th potency of estradiol). Water solubility is limited at ~0.5 mg/mL, which influences formulation strategies.
Reported Mechanism (Provisional)
Puerarin functions as a selective estrogen receptor modulator, binding to both ERα and ERβ receptors to promote cardiovascular protection. It enhances endothelial nitric oxide synthase (eNOS) activity, leading to increased nitric oxide production and improved vascular function. The compound also modulates calcium channels and inhibits inflammatory pathways including NF-κB signaling.
Clinical Narrative (Provisional)
A meta-analysis of 29 randomized controlled trials (n=2,480) demonstrated puerarin's efficacy in chronic heart failure, showing a 26% improvement in total effective rate (RR=1.26) and increased cardiac output (MD=0.45 L/min). Additional meta-analysis data shows a 38% improvement in acute heart failure treatment effectiveness (RR=1.38). The evidence quality is rated as moderate, with most studies conducted in Asian populations using dosages ranging from 400-800mg daily.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.